Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 32, Number 10—October 2026

CME ACTIVITY - Synopsis

Meta-analysis of Maternal and Fetal Outcomes of Crimean-Congo Hemorrhagic Fever during Pregnancy

Bahar Donk, Deniz Güllü, Ahmet Mirhan Cırık, Handan Alay, Faruk Karakeçili, Kemalettin Özden, Fatma Kesmez Can, Orçun Barkay, Natalia Pshenichnaya, and Önder ErgönülComments to Author 
Author affiliation: Graduate School of Health Sciences, Koç University, Istanbul, Turkey (B. Donk, D. Güllü); School of Medicine, Koç University, Istanbul (B. Donk, D. Güllü, Ö. Ergönül); Koç University—İşBank Center for Infectious Diseases (KUISCID), Istanbul (B. Donk, D. Güllü, Ö. Ergönül); School of Medicine, Marmara University, Istanbul (A.M. Cırık); School of Medicine, Atatürk University, Erzurum, Turkey (H. Alay, K. Özden, F.K. Can); School of Medicine, Binali Yıldırım University, Erzincan, Turkey (F. Karakeçili, O. Barkay); Central Research Institute of Epidemiology, Moscow, Russia (N. Pshenichnaya); Russian Medical Academy of Continuous Professional Education, Moscow, Russia (Ö. Ergönül)

Main Article

Table 3

Association of ribavirin usage with maternal death from a meta-analysis of maternal and fetal outcomes of Crimean-Congo hemorrhagic fever during pregnancy*

Cohort Outcomes reported, no. (%) Maternal death
 p value
No. (%) Odds ratio (95% CI)
Total cohort, n = 55
 52 (94.5)
 15 (28.8)
Ribavirin treatment reported† 43 (82.7) 0.171 (0.019–1.513) 0.112
No ribavirin 29 (67.4) 9 (20.9) Referent
Ribavirin
 14 (32.6)
 1 (2.3)
First trimester 6 (11.5) NA NA
No ribavirin 6 (100) 0
Ribavirin
 0
 0
Second trimester 16 (30.8) 3 (18.8) 2.750 (0.162–46.8) 0.489
No ribavirin 13 (81.2) 2 (66.7) Referent
Ribavirin
 3 (18.8)
 1 (33.3)
Third trimester 14 (26.9) 5 (35.7) 0.333 (0.132–0.840) 0.031
No ribavirin 8 (57.1) 5 (100) Referent
Ribavirin 6 (42.9) 0

*Bold font indicates statistical significance. NA, not applicable. †Includes case reports of determination of whether to administer ribavirin. Trimester at ribavirin administration was not reported for 5 patients, none of whom died.

Main Article

Page created: August 05, 2026
Page updated: September 28, 2026
Page reviewed: September 28, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external